What This Document Is
This is a student paper, completed for Drexel University’s Business Law I (BLAW 201) course. It analyzes an ethical dilemma involving a pharmaceutical company, a doctor, and the marketing of a new drug. The paper explores potential conflicts of interest, deceptive practices in clinical trials, and rationalizations for questionable behavior.
Why This Document Matters
This assignment is valuable for students enrolled in BLAW 201, or those studying business ethics and law. It serves as a high-achieving example (grade A+) of how to apply ethical frameworks – specifically the Blanchard and Peal approach – to a real-world business scenario. It demonstrates analytical writing skills and the ability to identify ethical issues within a complex situation.
Common Limitations or Challenges
This document is a single student’s perspective on a specific case study. It does not represent a comprehensive overview of pharmaceutical ethics or legal regulations. It is intended as a model for academic work, not as a definitive legal or ethical guide.
What This Document Provides
The full paper includes a detailed examination of the ethical concerns surrounding a doctor accepting payments to promote a drug, the use of a pre-written script, and the selective presentation of clinical trial data. It also discusses the concepts of rationalization and the difference between legal and ethical behavior. This preview *does not* include the full analysis, the application of the Blanchard and Peal framework, or the student’s personal reflections on the case.